{'_data': [['Unknown',
            [['GI',
              u'Abdominal pain 3.7 3.0 6.6 4.8 Dyspepsia 2.7 2.2 3.6 3.5 Acid regurgitation 1.9 2.4 2.0 4.3 Nausea 1.9 2.4 3.6 4.0 Abdominal distension 1.0 1.4 1.0 0.8 Constipation 0.8 1.6 3.1 1.8 Diarrhoea 0.6 0.5 3.1 1.8 Dysphagia 0.4 0.5 1.0 0.0 Flatulence 0.4 1.6 2.6 0.5 Gastritis 0.2 1.1 0.5 1.3 Gastric ulcer 0.0 1.1 0.0 0.0 Oesophageal ulcer 0.0 0.0 1.5 0.0 Musculoskeletal Musculoskeletal (bone, 2.9 3.2 4.1 2.5 muscle or joint) pain Muscle cramp 0.2 1.1 0.0 1.0 Neurological Headache 0.4 0.3 2.6 1.5 The following adverse experiences have also been reported during clinical studies and/or post-marketing use: [Very common (\u2265 1/10), Common (\u2265 1/100 to < 1/10), Uncommon (\u2265 1/1,000 to < 1/100), Rare (\u2265 1/10,000 to < 1/1,000), Very rare (< 1/10,000), not known (cannot be estimated from the available data)] Immune system disorders: Rare: hypersensitivity reactions including urticaria and angioedema Metabolism and nutrition disorders: Rare: symptomatic hypocalcaemia, often in association with predisposing conditions Nervous system disorders: Common: headache, dizziness Uncommon: dysgeusia Eye disorders: Uncommon: eye inflammation (uveitis, scleritis, episcleritis) Ear and labyrinth disorders: Common: vertigo Gastrointestinal disorders: Common: abdominal pain, dyspepsia, constipation, diarrhoea, flatulence, oesophageal ulcer , dysphagia , abdominal distension, acid regurgitation Uncommon: nausea, vomiting, gastritis, oesophagitis , oesophageal erosions , melena Rare: oesophageal stricture , oropharyngeal ulceration , upper gastrointestinal PUBs (perforation, ulcers, bleeding) Skin and subcutaneous tissue disorders: Common: alopecia , pruritus Uncommon: rash, erythema Rare: rash with photosensitivity, severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis Musculoskeletal and connective tissue Very common: musculoskeletal (bone, muscle or disorders: joint) pain which is sometimes severe Common: joint swelling Rare: Osteonecrosis of the jaw , atypical subtrochanteric and diaphyseal femoral fractures (bisphosphonate class adverse reaction) \u22a5 General disorders and administration site Common: asthenia , peripheral oedema conditions: Uncommon: transient symptoms as in an acute phase response (myalgia, malaise and, rarely, fever), typically in association with initiation of treatment \xa7 See section 4.4 Frequency in clinical trials was similar in the drug and placebo group * See sections 4.2 and 4.4 \u2021 This adverse reaction was identified through post-marketing surveillance. The frequency of \u201crare\u201d was estimated based on relevant clinical trials \u22a5 Identified in post-marketing experience']]]],
 '_pages': [6, 7],
 u'_rank': 1,
 u'_type': u'LSFU'}